3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Psoriasis
1
Neoplasms
1
Lymphoma, Follicular
1
Inflammatory Bowel Diseases
1
Colorectal Neoplasms
1
Colitis, Ulcerative
1
Adenoma
1
Interventions
etrolizumab
5
Infliximab
4
Adalimumab
3
golimumab
2
CT-P13
2
peficitinib
1
Sutures
1
Surgical Instruments
1
Ringer's Lactate
1
Proctectomy
1
Pneumococcal Vaccines
1
Papillomavirus Vaccines
1
Methylprednisolone
1
Mesalamine
1
Lysine Acetyltransferase 5
1
Laparoscopy
1
Injections
1
Hydroxyethyl Starch Derivatives
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Eicosapentaenoic Acid
1
CVD protocol
1
ABX464
1
2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colitis, Ulcerative
×
Mesalamine
×
Clear all
NCT02093663
2021-06-09
PACE
Takeda
Phase 3
Completed
107 enrolled
18 charts